This section of pediculosis.com is devoted to news about worldwide regulatory and legal changes affecting the head lice industry.
In an effort to control the head lice infestations and drug resistance to the most commonly used head lice treatments, the US Food and Drug Administration (FDA) has issued a new guidance on developing topical drugs.
The Federal Trade Commission has fined the manufacturer of Lice Shield $0.5M for misleading advertising claims.
A recent decision by the US Federal Trade Commission (FTC) requires that advertising claims by makers of Best Yet! head lice products receive Food and Drug Administration (FDA) pre-approval.
A petition requesting that lindane be withdrawn from sale as a second-line pediculicide has been denied by the US Food and Drug Administration (FDA).
The US Food and Drug Administration (FDA) is introducing new requirements and responsibilities for the registration and listing of Medical Devices, effective October 1, 2012.
The US Food and Drug Administration (FDA) have been urged to prevent the use of lindane in topical pediculosis treatments for children.
The Public Health Medicine Environmental Group (PHMEG) has recently released updated guidelines for diagnosis, preventation and treatment of head lice infection. This is a revised version of the 2008 update.